Fierce Pharma November 16, 2023
Angus Liu

Watch out, Pfizer and Roche. Thanks to an acquisition and now an FDA approval, Bristol Myers Squibb is entering a niche lung cancer market.

The FDA has cleared Bristol Myers’ repotrectinib, to be branded as Augtyro, to treat non-small cell lung cancer (NSCLC) patients whose tumors have ROS1 oncogenic fusions. The New Jersey pharma company said it plans to make the drug available starting in mid-December.

BMS got Augtyro through its $4.1 billion acquisition of Turning Point Therapeutics last year. And Wednesday’s approval gives BMS an opportunity to challenge Pfizer’s Xalkori and Roche’s Rozlytrek in ROS1-positive NSCLC, which accounts for about 1% to 2% of all NSCLC cases.

Augtyro could reach $1.4 billion sales at peak in the first-line...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients
Latigo raises $150M to get non-opioid pain drugs through key tests
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition
CMS doubles down on Medicare drug price negotiations
Drug shortages could surge 25% as AI reshapes specialty pharmacy: Survey

Share This Article